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ELSEVIER
The Regulation of CD llb Integrin 
Levels on Human Blood Leukocytes and 
Leukotriene B4'Stimulated Skin by a Specific 
Leukotriene B4 Receptor Antagonist (LY293111)
JPA van P eh,*t Elke MGJ de Jong *  Piet E] van Er p*
Malcolm I Mitchell,£ Philip Marder,§ Stephen M Spaeths,§ 
Candida AEM  van Hooijdonk,* Astrid LA Kuijpers* and Peter CM van de Kerkhof*
’" D e p a r t m e n t  o f  D e r m a t o l o g y ,  U n i v e r s i t y  H o s p i t a l  N ijm e g e n ,  P.O. Box 9101, 6500 HB, N ijm e g e n ,  T h e  
N e t h e r l a n d s ,  $Lilly R e s e a r c h  C e n t r e  L im ite d , E r l  W o o d  M a n o r ,  W in d l e s h a m ,  UK a n d  § L ii . ly  R e s e a r c h
L a b o r a t o r i e s , In d i a n a p o l i s , IN, U S A
ABSTRACT. C D llb  is part of the (32-integrin Mac-1 and plays an important role in neutrophil adhesion. 
Leukotriene B4 (LTB4) is an active upregulator of neutrophil CDllb-expression, acts as a potent chemoattrac- 
tant to neutrophils and is also known to upmodulate epidermal proliferation. We performed a placebo-controlled 
study on LY293111, an oral LTB4 receptor antagonist. Twenty healthy male volunteers were randomised over 
three treatment groups that received placebo, 48 mg, or 200 mg drug twice daily for 10 days. Before and after 
treatment, flow cytometrical CD1 lb assessment was performed on in vitro LTB4-stimulated peripheral blood 
neutrophils. Additionally, skin biopsies were taken at 24 and 72 h after epicutaneous LTB4 application, before 
and after treatment. The effects on skin were assessed immunohistochemieally using various markers. Ail 
observed effects were dose related. C D llb  upregulation on blood neutrophils was significantly suppressed in both 
treatment groups compared to placebo. In skin, a significant suppression of inflammation and hyperproliferation 
occurred. Pronounced inhibition was observed on neutrophil migration into the epidermis and the inflammatory 
infiltrate was decreased. A similar but weaker response was seen in the dermis. The number of cycling cells 
as well as suprabasal keratin-16 expression were decreased in both treatment groups. LY293 111 proved to be 
a potent inhibitor of LTB4-induced cutaneous inflammation and hyperproliferation. The potent antiinflam­
matory effect in vivo and the fact that in the present study the compound showed no clinically significant side 
effects make it an interesting drug in the future treatment of inflammatory conditions predominated by neu­
trophils. b io c h e m  p h a r m a c o l  53;7:1005-1012, 1997. © 1997 Elsevier Science Inc.
KEY WORDS. LY293 111; skin; inflammation; neutrophils; integrins, leukotriene B4
The arachidonic acid cascade plays an important role in 
inflammation. It is the precursor of prostaglandins, throm­
boxanes, hydroxyeicosatetraenoic acids, and leukotrienes 
[1], This latter group is important in the induction of poly­
morphonuclear leukocyte (PM N)^ aggregation and adhe­
sion, production of superoxides, and chemotaxis [2, 3]. Leu­
kotrienes are 5-lipoxygenase products of arachidonic acid 
and consist of various inflammatory eicosanoids [4]. Leuko­
triene B4 (LTB4) is a potent chemo attractant for PMN and 
might together with 12-hydroxyeicosatetraenoic acid play an
t  Corresponding author: JPA van Pelt* Department of Dermatology, Uni­
versity Hospital Nijmegen, P.O. Box 9101, 6500 HB, Nijmegen, The
Netherlands T e l  +31 24 3617245, FAX: +31 24 3541184.
^  Abbreviations: LTB4, Leukotriene B4; PMN, polymorphonuclear leu­
kocytes; ICA M 'l, intercellular adhesion molecule 1; EDTA, ethylene-di- 
am ine-tetra-acetic-acid; RAM , rabbit-antimouse ant 
3-amino-9**ethyl-carbazole; PAP, peraxidase-antiperoxidase technique; 
HUVEC, human umbilical vein endothelial cells.
Received 9 July 1996; accepted 12 November 1996.
important role in many inflammatory processes [4]. Indeed, 
inhibitors of the enzyme 5- lipoxygenase have proven to be 
beneficial in the treatment of several inflammatory ct
tions [5-
PMN play an important 
These cells have an
ì i n  c 4 \ r «
role in the iniri
the maintenance of various inflammatory diseases 
10]. PMN are attracted by numerous chemokines and
metabolites of the arachidonic acid ease 
and GRO-a [11], Migration of PMN 2 mtravas
y
«1 «*
compartment to the extra vascular space is a mechanism 
that requires interaction through )n mo
the cell surface of PMN as well as on tissue cells and matrix. 
Human PMN adherence to endothelial cells can be en-
hanced by a variety of inft 
For PMN interaction with
mediators in vitra [12]. 
cells and intercellular ma-
trix, the a.m32'integrins, and in particular CD11/CD1B, are 
considered to be important [12-14]. The significance of
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individual integrin heterodimers in the various stages of 
PMN migration in vivo is not yet fully clarified. The clinical 
relevance, however, is demonstrated in Leukocyte Adhe­
sion Deficiency syndrome, in which PMN lack surface ex­
pression of (32-integrins, and is associated with a short life 
expectancy due to severe inflammatory complications [15]. 
C D llb/CD 18 is usually referred to as the Mo-1 or Mac-1 
receptor. Known ligands are C3bi, Fx, Fb, and intercellular
adhesion molecule 1 (ICAM-1) [16, 17]. ICAM-1 is mainly
expressed by endothelial cells and to a lesser extent by
keratinocytes [18].
Hpicutaneous application of LTB4 on human skin results 
in a reproducible dose-dependent cutaneous inflammatory 
response, initially dominated by PMN with a maximum 
presence at 24 hr, and followed by a dermal T-cell infiltrate, 
which is most pronounced after 72 hr [19]. Epidermal hy­
perproliferation occurs, reaching a maximum after 72-96 
hr. Therefore, this model has been used previously to study 
sequential changes in aspects of cutaneous inflammation 
and interference in this process by antiinflammatory thera­
pies [3],
Recently, the new specific oral LTB4 receptor antagonist 
LY293 111 (Lilly Research Laboratories, Indianapolis, IN, 
USA) has been developed. In vitro it has proven to be a 
potent inhibitor of the LTB4 receptor 120]. In addition, it 
specifically inhibits chemotactic activity, calcium mobili­
sation, chemiluminescence, superoxide generation, and in-
of CD1 lb/CD 18 integrin upmodulation in LTB4-
stimulated neutrophils in vitro [20].
In this study, the following questions were addressed: 
is LTB4-induced PMN accumulation in normal skin 
inhibited by a 10 days treatment course with LY29.3111 as
to placebo; > LY293111
C D llb  expression on PMN in blood or skin and to what 
extent; third, are late effects of epicutaneous LTB4 appli­
cation modified (epidermal hyperproliferation and T-cell 
influx); and last, what is the clinical tolerability of the drug?
MATERIALS AND METHODS
Study Design
Clinical and Laboratory Safety Measurements
Prior to starting medication, a general physical examina­
tion and laboratory measurements were performed. The 
laboratory measurements consisted of: haematology (total 
and differential white blood cell counts, erythrocyte count, 
mean cell volume, mean cell haemoglobin, mean cell hae­
moglobin concentration, haemoglobin, haematocrit, and 
platelet count); blood chemistry (ASAT, ALAT, bilirubin, 
alkaline phosphatase, gamma-GT, urea, creatinin, uric 
acid, phosphorus, calcium, total protein, creatin kinase, and 
thyroid function tests); electrolytes 
chloride, bicarbonate); and random blood glucose. In 
tion, urinalysis was performed (specific gravity, pH, protein, 
glucose, ketones, bilirubin, urobilinogen, and sediment). 
During the study period, the haematology, blood chemistry, 
and urinalysis were repeated at day 1, 15, and the last day 
of the study.
LTB4 Application and Biopsy Procedures
LTB4 was applied epicutaneously to all volunteers before 
treatment and after 8 days of treatment. A 4-mm punch 
biopsy was taken on each voluteer before application to 
assess histology of the unchallenged skin. Aliquots of 100 
ng LTB4 (Paesel GmbH, Frankfurt, Germany) dissolved in
10 jxl of ethanol were applied on the skin of the upper part 
of the back of the volunteers via a plastic cylinder (6.5 mm 
diameter) and the ethanol was evaporated under a stream of 
nitrogen. The test sites were covered with impermeable 
dressings (Silver patch, van der Bend BV, Brielle, The 
N etherlands) and held in place with leukosilk tape 
(Beiersdorf, Hamburg, Germany).
Biopsies were taken on days 2 and 4 (before administra­
tion of the compound), and on days 16 and 18 (during the 
10 day treatment course with the compound) after injec­
tion of a local anaesthetic. The biopsies were washed in
phosphate- 
O CT compound
frozen in
saline in Tek
ific, Elkhart, IN, USA)
and at °C until use
Prior to initiation of the study, approval from the Medical 
Erhics Committee was obtained. The trial was 
a double-blind, placebo-controlled n 
with three parallel groups. Twenty healthy male volunteers 
(20-42 years of age, mean age 27) participated in this study, 
informed consent was obtained from all volunteers, none of 
whom had any history or signs of skin disease. No medica­
tion other than the compound was to be administered for at 
least 7 days before and during the study. For minor com­
plaints paracetamol was ;
All volunteers were treated with LY293111 or placebo 
for 10 days. Six volunteers received LY293111 orally at a
dose of 200 mg twice daily, seven volunteers received the 
compound at a dose of 48 mg twice daily, and seven vol­
unteers received placebo. The study period lasted 32 days.
CD l i b  Integrin Upregulation Assay
assessment of ex vivo C D llb  surface 
expression were obtained on day 1 prior to the first LTB4 
:hallenge and on day 15 (after 7.5 days of treatment with
LY293111 or placebo) prior to the second LTB4 challenge.
Peripheral blood (4 ml) was collected through vene­
puncture, kept in ethylene-di-amine-tetra-acetic-acid
(EDTA) at 4°C and processed within 3 hr after collection
nonspecific upregulation of C D llb  surface ex- 
a result of neutrophil activation. Blood samples 
were processed in triplicate using 90 |xL aliquots that were
with LTB4 (10 j j l I  1 x 10“7 M) in Hanks' bal-
anced salt solution (HBSS, Sigma Chemical Corp., St. 
Louis, MO, USA) containing 0.1% bovine serum albumin 
(BSA), or with HBSS (10 |xl) alone for 30 min at 37°C.
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Samples were then cooled and incubated in the dark for 30
min at 4°C with 10 |xL (0.045 g/l) antihuman C D llb -
fluorescein conjugate (M o-1-FITC, Coulter Corp., Hialeah, 
FL, USA). Erythrocytes were lysed and the remaining cells 
were washed with HBSS-BSA, fixed in 1% paraformalde- 
hyde solution and stored at 4°C until analysis. The analysis 
was always performed within 1 week after preparation of the
Flow Cytometric Analysis
All specimens were analysed on an Epics Elite Flow Cy- 
tometer (Coulter, Luton, UK). Cells were excited with an 
air-cooled 488 nm argon laser set at 15 mW. FITC fluores­
cence was measured through a 525 nm (band width 30 nm) 
band pass filter. Calibration and sensitivity were checked by 
using FITC-labelled beads (Standard-Brite, Coulter Source, 
Hialeah, FL, USA). Forward and side scatter were used for 
gating granulocytes only. For each sample 5,000 gated cells 
were analysed.
Immunohistochemical Staining Procedures
Cryostat sections of 7 |xm were cut and fixed for 10 min in 
acetone/ether (60/40 vol.%) for Mib-1, or in acetone for 
staining with the other antibodies. Table 1 depicts the vari­
ous markers used. Staining with Ks8.12, Mib-1, anti-elas- 
tase, an ti-C D llb , and anti-ICAM-1 was performed using
2s werean indirect peroxidase 
with the monoclonal antibodies for 30 min, and after two 
washes with PBS incubated with rabbit-antimouse antibody
(RAM, Dakopatts, Copenhagen, Denmark) 
with peroxidase for 30 min.
Staining with T 1 1 and T6 was done using a peroxidase- 
antiperoxidase technique (PAP technique). Slides were in­
cubated with the monoclonal antibodies for 60 min. After 
two washes with PBS, the slides were incubated with RAM 
immunoglobulins (RAM-lg, Dakopatts, Co 
mark) and after two more washes with 
(Dakopatts, Copenhagen, 
cubation with RAM-lg t 
more washes with PBS and 
etate buffer, pH 4.9, slides
il
complexes
buffer containing 200 mg/1 3-amino-9- *  *c
(AEC solution) and 0.01% H iO 2 10 min at 37°C in
All slides were t n It
slightly counterstained with Mayer’s Haematoxylin
finally mounted in gSt. Louis, MO, 
erin gelatin and s
Histological Examinations
Epidermal proliferation was measured by counting the num­
ber of Mib-1-positive nuclei per mm length of section. 
Ks8.12 binding of the epidermis was assessed in the basal 
and suprabasal compartment using a seven-point scale: 0 »
sporadic staining, 2 = minimal staining,no
31.-I
5
1
ate staining, 4
staining, 6
staining 1
:te staining
ïnsity of PMN (elastase and C D llb  scannings),
ocytes, and Langerhtins cells were assessed semi-
TABLE 1. Markers used for histology and in the C D llb  upregulation assay
Cell type Antibody Ig-type Ligand Clone Specificity
Concen­
tration
(p.g/mL) Manufacturer
PMN anti-elastase leG,
kappa
neutrophil 
elas tase
NP57
mouse
neutrophil elastase in 
PMN, sporadic in 
monocytes
6 1.5 Dakopatts, Copenhagen, 
Denmark
T-lymphocytes T i l
kappa
CD 2 MT910
UK hi se
CD2 155 Dakt »patis, ( a»penhagen, 
Denmark
Lange rhans 
cells
T6 liA «
kappa
CD la NA 1/M
mouse
CD I a 337 Ortho Diagnostics Sys­
tems, Raritan, NJ,
USA
Cycling cells Mib-1 IgG, K167 Mib-1
mouse
nuclear antigen present
in the late Gj, S and
G2 + M phases of the 
cell cycle
200 Immunoteeh, Marseille, 
France
Cytokeratin 16-
positive cells
Ks8.12 IrO. Cytokeratin
16
K8.12
mouse
hyperproliferative epider­
mis, cross reaction 
with cytokeratin 13, 
which is mainly pres­
ent in hair follicles
Sigma, St. Louis, MO,
USA
GDI lb-positive 
cells (in skin)
anti-GDI lb IrC ! CD 11 b Rear-1 
mouse
PMN, some monocytes, 
and macrophages
Monosan, Uden, The 
Netherlands
ICAM-1 -positive 
cells
ICAM-1 IgGi CD 5 4 84H10
mouse
CD54 200 1 mmu notec h, M arse i I le, 
France
GDI lh-positive 
cells (in blood)
anti-GDI lb IgM
kappa
C D llb 94 PMN, some monocytes, 
and macrophages
Monosan, Uden, The 
Netherlands
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quantitatively in epidermis and dermis using a seven-point 
scale: epidermis: 0 = no positive cells observed, 1 = sporadic 
staining, 2 = minimal presence, 3 = moderate presence, 4 = 
moderate/pronounced presence, 5 = pronounced presence, 
6 = complete staining. Dermis: 0 = no positive cells, 1 =
= 1—25% of infiltrate cells stained, 3 = 26—50%, 
4 = 51—75%, 5 = 76-99%, 6 = 100%. The dermal infiltrate
was subdivided in perivascular and diffuse localization. 
ICAM-1 staining was quantified in epidermis and dermis 
using a five-point scale: 0 = no staining, 1 = 1-25%, 2
26-50%, 3 = 51-75%, 4 = 76-100%. In
mation of the total infiltrate was made using a four-point 
scale: 0 = no infiltrate present, 1 = minimal infiltrate, 2 =
moderate infiltrate, 3 =
Statistical comparisons between groups were carried out 
before and after LY293 111 treatment. After treatment, the 
placebo group was compared to both LY293111-treated 
groups. For statistical evaluation the Mann-Whitney test 
was used.
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FIG. 1. Ex vivo C D llb  expression in unstimulated and 
LTB4-stimulated peripheral blood neutrophils, before and 
after treatment. The results are expressed as a ratio 
CD1 lb stlmulttted/C D l lb un8timuiated per treatment group 
(mean ± SEM). □: before treatment, ■: after treatment.
RESULTS
Clinical Results
No clinically significant toxicities were observed. There 
were no dropouts. The safety urine and blood measurements 
remained within normal ranges. LTB4 application was well 
tolerated. The histological observations within each sub­
group proved to be reproducible.
Flow Cytometry
Ex vivo challenge of blood PMN with LTB4 before treat­
ment showed a highly reproducible and consistent upregu-
lation of GDI lb ì treatment, no statisti-
cally significant difference was seen in the relative neutro­
phil C D llb  expression (ratio challenged/unchallenged,
expressed as a fold increase) between the various treatment
± SEM], low-dosegroups (placebo: 3.12 ± 0.49 [mean
LY293111: 2.60 ± 0.27, and high dose: 2.63 ± 1.02, Fig. 1).
After systemic treatment, the placebo group s
ince in the relative neutrophil C D llb  expression
:ompared to before administration (2.34 ± 0.24). A highly
icant reduction was reached with high dose LY293 111
(1.02 ± 0.02, p = 0.0027). The low dose group also showed 
a significant reduction (1.17 ± 0.05, p •  0.0017) (Fig. 1).
The mean relative expression of C D llb  after ex vivo 
LTB4 challenge on blood neutrophils permitted a total 
separation between placebo-treated and LY293111-treated
treatment, LTB4-induced Mib-1 expression was comparable 
to the response before treatment, whereas the induction of 
Mib-1 staining was decreased in the low dose group and 
virtually absent in the high-dose group (p = 0.01 and p =
0.003 respectively, Figs. 2 and 3).
CYTOKERATIN 16. Ks8.12 staining was sporadically pres­
ent in normal unchallenged skin. After LTB4 application, a 
statistically significant increase of keratin staining had al­
ready occurred after 24 hr. Skin specimens from volunteers 
receiving LY293 111 showed a significant decrease of kera­
tin staining after 24 hr compared to the placebo group (p =
0.02 in the low and p = 0.004 in the high dose group). In
the high dose group, this decrease persisted until 72 hr after
LTB4 application (p = 0.005).
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Irnmunohis tochemis try
EPIDERMAL PROLIFERATION: CYCLING CELLS. The num­
ber of cycling epidermal cells showed a repri
sponse 11 ) L 4 ore systemic treatment: fi
; re
i a
s light reduction after 24 hr, a marked increase was
at 72 hr r I 4 challenge (Fig. 2). During placebo
FIG. 2. Number of Mib-1-positive nuclei indicating cycling 
cells. The results are expressed per mm length of epidermis, 
before and after treatment with LY293111 (median ± SD). 
open column: normal epidermis, horizontal rule column: 
before treatment 24 hr after LTB4 stimulation, solid col­
umn: before treatment 72 hr after LTB4 stimulation, slanted 
rule column: after treatment 24 hr after LTB4 stimulation, 
vertical rule column: after treatment 72 hr after LTB4 
stimulation.
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FIG. 3. Mib-1'Stained nuclei 72 hr after application of LTB4 
on normal skin (scale bars 100 jim). (A): placebo, (B): 200 
mgLY293111 BID.
INFLAMMATION: TOTAL INFILTRATE CELLS. A substan-
increase was observed at 24 and 72 hr following LTB4
in ill volunteer systemic
treatment. After treatment with placebo, this increase was 
virtually identical. In contrast, high-dose LY293 111 in­
duced a pronounced reduction of cutaneous inflammation 
which was most 
0 .012).  
pattern (Fig. 4).
ELASTASE STAINING. LTB4 challenge induced a maxi­
mum elastase expression after 24 hr in epidermal and der­
mal skin compartments, one 
after 72 hr. Again, all three volunteer groups s
: treatment. In con
a
trast, during systemic treatment, the accumulation of elas- 
tase-positive cells was inversely correlated to the dose of
3.0
2.5
2.0
1.5
5 1.0
0.5
0.0
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te s o t i  .
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FIG. 4. Infiltrate cells, before and after treatment (median * 
SD). Open column: normal unchallenged skin, horizontal 
rule column: before treatment 24 hr after LTB4 stimulation, 
solid column: before treatment 72 hr after LTB4 stimula­
tion, slanted rule column: after treatment 24 hr after LTB4 
stimulation, vertical rule column: after treatment 72 hr after 
LTB  ^ stimulation.
LY293 111: a significant reduction in the epidermal accu­
mulation was seen during low-dose treatment 24 hr after 
LTB4 challenge (p = 0.03), whereas in the high-dose group 
epidermal PMN accumulation was virtually completely sup­
pressed (p = 0.005). At 72 hr, the differences between the 
three groups had diminished considerably, but there was 
still a decreased expression in the high-dose group (p * 
0.05), Twenty-four hours after LTB4 challenge, the aceu
mulation of PMN diffusely in
0 0
was
during high-dose treatment (p = 0.04). PMN accumulation
was not s
remi
in
acent to
GDI IB STAINING.
systemic treatment, i 
cumulation after 24 hr in all skin
a ac
treatment
s was com­
at 24 and 72 hr (|> »1* 0¡f / iv a i & i
and 6). Diffusely locateli dermal C D lllv
s were tit 24 hr alter LTIl, ;
(Í) 0.02). Low-dose LY295111 m a
ìcation
accumulation of e * ■''-positive cells
T-LYMPHOCYTE STAINING. In contrast to the marked in­
terference of LY29.3 111 with PMN migrat ion, the effects on 
T -lym phocytes were m odest. A ccum ula tion  of T- 
lymphocytes in the epidermis and diffusely in the dennis 
was low in all three treatment groups. However, 72 hr after
i cat ion, a m t h e of
,'s in
accomplished in the high-dose group (p
LANGERHANS CELL STAINING.
0.01).
s m
it i on
showed a si
ic treatment. All three treatment groups 
pattern after administration of the com-
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FIG. S. Epidermal C D llb  staining before and after treat- 
ment with LY293111 (median ± SD). Open column: normal 
epidermis, horizontal rule column; before treatment 24 hr 
after LTB4 stimulation, solid column: before treatment 72 
hr after LTB4 stimulation, slanted rule column: after treat­
ment 24 hr after LTB4 stimulation, vertical rule column: 
after treatment 72 hr after LTB4 stimulation.
pound. No significant changes in the epidermal T6-positive 
cells were recorded. The dermal compartment reflected a 
slight increase in T6-positive cells at 72 hr in the untreated 
and placebo-treated groups. A t this time point, the sub­
group receiving high-dose LY293 111 demonstrated a sig­
nificantly lower number of perivascular T6-positive cells (p
= 0.04).
ICAM-1 STAINING. Epidermal ICAM-1 staining was lo­
cally present in normal unchallenged skin. In the pretreat­
ment specimen, a consistent increase of ICAM-1 in epi-
was seen at 24 and 72 hr after LTB i
. After treatment, a 
of epidermal ICAM-1-positive cells was observed in the 
high-dose group at 24 hr (ƒ> = 0.01). After 72 hr, however,
ICAM-1 expression in the epidermis was comparable to the 
other two groups and equivalent to before treatment.
In contrast, the increase of ICAM-1 diffusely in the der­
mis, as seen in the placebo-treated and untreated skin, was 
substantially inhibited by high dose treatment at 72 hr (])
. Perivascular ICAM-1 
before and after treatment.
rem;
DISCUSSION
A 10-day treatment course with LY293111 showed marked 
influences on peripheral blood PMN, epidermal prolifera­
tion, and cutaneous inflammation. The treatment showed
no silì cant s
potent inhib ition  of
PMN. LT1V¡
was the 
on peripheral
epidermal hyper
was virtually a  
associatei.1 keratins s 
high-dose trea t men t . 
Infiltrate cells were
ration
rat ton-
following
LY293111
f t
FIG. 6. C D l lb  staining 24 h r after application of LTB4 on 
norm al skin (scale bars 100 jam). (A): placebo, (B): 200 mg
LY293111 BID.
had a reproducible dose
PMN C D l l b i m a a e s
sion of C D l l b  upregulation in volunteers 
high dose, and a significant reduction in 
ment group. Migration of 
tase-positive cells was blocked at
it the
i  i n m inhibition of PMN
rivascular level,
in the
epidermis and diffusely in the dermis after 24 and 72 hr. 
The discrepancy between marked inhibition of epidermal 
and diffuse dermal PMN accumulation on the one hand 
and the unaffected perivascular presence of PMN on the 
other suggests an effect of LY293111 on PMN migratory
ar space into stroma <
the number of 
and T-lymphocytes 
accumulating in the high-dose treat-
dermis. In the perivasc
L
were
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ment group 72 hr after LTB4 application. Epidermal
ICAM-1 was increased 24 hr after LTB4 challenge in the
high-dose group, and decreased diffusely in the dermis 72 hr 
after application, in contrast to the other two treatment 
groups. Perivascular ICAM-1 upregulation persisted after 
treatment with LY293111. Based on these observations, we 
may construct the following response pattern to LY293 111 
in LTB4-induced cutaneous inflammation. PMN (as as­
sessed by elastase) accumulate in the perivascular zone but 
fail to migrate into the stroma and epidermis. CD1 lb- 
positive cells showed the same distribution pattern. During 
treatment, the decreased presence of T-lymphocytes in the 
perivascular zone suggests inhibition of accumulation of T- 
lymphocytes. Diffusely in the dermis, the relative sparsity of
PMN and T-cells is accompanied by a lack of ICAM-1 
expression. The late events following LTB4 application (i.e. 
epidermal hyperproliferation and expression of keratin 16) 
are prevented by pretreatment with LY293111.
LY293 111, a specific LTB4 receptor antagonist, proved 
to suppress C D llb  induction on peripheral blood PMN. 
The observation that PMN in skin keep their ability to 
adhere to endothelium and move through the vessel walls, 
but lose their ability to migrate through the stroma, gives 
rise to speculation concerning specific functions of CD llb. 
Indeed, Furie et al. [21] studied the adhesion to and migra­
tion of neutrophils across human umbilical vein endothelial 
cells (HUVEC) in an in vitro model. Monoclonal antibod­
ies to C D llb  substantially inhibited migration of neutro­
phils. M onoclonal antibodies to ICAM-1 decreased 
transendothelial chemotaxis. This effect is mediated by 
binding of the antibody to ICAM-1 on HUVEC and not by
a direct effect of the antibody on neutrophils. Therefore, 
migration seems dependent on CD1 lb and transendothelial 
chemotaxis on ICAM-1. In addition, Vedder et al. [22] 
showed that ICAM-1 is essential in adherence of PMN to 
endothelium, and that increased expression of C D llb / 
CD18 is not. This might explain why PMN still adhere to 
endothelium and show diapedesis but fail to migrate into 
the stroma when CD1 lb  is decreased during treatment with 
LY293111. It is striking that late events in the LTB4 model 
do not take place when PMN are restricted to the perivas­
cular compartment, although LTB4 itself might induce 
these late effects. In the high-dose group, hyperproliferation 
and epidermal PMN influx were strongly inhibited. By con­
trast, hyperproliferation did not occur in the low-dose 
group, whereas a small percentage of PMN were still able to 
migrate into the epidermis. One might speculate that epi­
dermal hyperproliferation and associated features are possi­
bly modulated by the LTB4 receptor antagonist and not 
exclusively secondary to the intraepidermal migration of
PMN.
ICAM-1 has been reported to be expressed by activated 
endothelial cells, monocytes, B- and T-lymphocytes, and 
keratinocytes [23]. Increased ICAM-1 expression has been 
described on cells under inflammatory conditions such as 
psoriasis, atopic dermatitis, lichen planus, and in rheuma­
toid synovium [24-26]. In psoriasis, the development of 
manifest lesions is linked with the appearance of ICAM-1 
positivity on keratinocytes [27]. After LTB4 application, an 
increase of dermal diffuse ICAM-1 was observed after 7 2 h, 
one that is prevented by LY293111. It is feasible that 
LY293111 is capable of preventing upregulation of ICAM-1 
in incipient psoriatic lesions, thereby preventing the induc­
tion or spreading of the disease. There is a substantial vari­
ability in epidermal ICAM-1 expression possible between 
different individuals. This could be an explanation for the 
profound increase in epidermal ICAM-1 expression in the 
high-dose group. However, the difference with the other 
two treatment groups is striking.
Blocking of C D llb  using monoclonal antibodies pre­
vents PMN adhesion to keratinocytes [28]. Furthermore, 
functional CD1 lb has been reported to be decreased in the 
development of autoimmune neutropenia [29]. Wu et al. 
[30] showed that CD1 lb/CD18 may participate in the acute 
expression of glomerular damage in nephrotoxic nephritis. 
In addition, CDllb/CD18 has been reported to be of im­
portance in septic liver injury [31] and in reperfusion- 
induced albumin leakage inducing microvascular dysfunc­
tion [30].
Therefore, C D llb  likely plays an important role in many 
diseases and interference with upregulation may form an 
important clinical target in management of these diseases.
A total separation between placebo-treated volunteers 
and LY293Ill-treated volunteers was possible with respect 
to PMN CD llb upregulation in blood. In skin, however, 
high-dose treatment is necessary to achieve complete
blocking of PMN influx. LY293111 decreases LTB4-
induced cutaneous proliferation, prohibits spreading of 
PMN and decreases extravasation of T-lymphocytes. LTB4 
levels are increased in psoriatic skin lesions [32], and im- 
munohistochemical changes as seen after epicutaneous 
LTB4 application have been found in lesional skin of pso­
riatic patients [24, 33]. Various compounds that interfere 
with LTB4 metabolism such as 5-lipoxygenase inhibitors 
proved to be effective in psoriasis [5,6]. Unfortunately, side 
effects have limited their use until now. The present study 
suggests that the pharmacological profile of LY293111 is 
very attractive: substantial effects on cutaneous inflamma­
tion, and absence of clinically significant side effects in the 
20 subjects at the dosage used. In diseases that are initiated, 
dominated or maintained by PMN, LY293111 may well be 
beneficial.
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